查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1728083

偏头痛治疗市场－全球产业规模、份额、趋势、机会和预测，按治疗学、给药途径、配销通路、地区和竞争细分，2020 年至 2030 年预测

Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutics, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球偏头痛治疗市场价值为 38.9 亿美元，预计到 2030 年将达到 50.1 亿美元，预测期内复合年增长率为 4.31%。由于偏头痛发病率的上升、患者意识的增强以及药物开发的快速进步，该市场正在稳步扩大。偏头痛是一种慢性神经系统疾病，影响着全球大量人口，因此对有效的治疗方案的需求十分强烈。在降钙素基因相关胜肽 (CGRP) 抑制剂和 gepants 等持续创新的支持下，治疗正在朝着更有针对性和个性化的方向发生显着转变，这些创新已显示出良好的临床效果。人们对偏头痛对公共健康和经济影响的认识不断提高，也推动了公共和私营部门对研发的投资。随着製药公司专注于推出下一代药物和生物製剂，市场继续朝着更有效和个人化的治疗策略发展。这些创新，加上人们意识的提高和医疗保健管道的改善，预计将支持市场持续成长。

市场概览
预测期 2026-2030
2024年市场规模 38.9亿美元
2030年市场规模 50.1亿美元
2025-2030 年复合年增长率 4.31%
成长最快的领域 止痛药
最大的市场 北美洲

关键市场驱动因素

偏头痛盛行率高

主要市场挑战

药物开发的复杂性

主要市场趋势

精准医疗

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：临床试验分析

第五章：顾客之声

第六章：全球偏头痛治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗学分类 {止痛药（镇痛药、曲坦类药物、麦角生物碱等）及预防药物（降血压药、抗惊厥药、降钙素基因相关胜肽 (CGRP) 拮抗剂、其他预防疗法）}
    • 依给药途径（口服及鼻腔给药、注射剂）
    • 按配销通路（零售药房、医院药房、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第七章：北美偏头痛治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第八章：欧洲偏头痛治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第九章：亚太偏头痛治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 10 章：南美洲偏头痛治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章：中东和非洲偏头痛治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 12 章：市场动态

  • 驱动程式
  • 挑战

第十三章：市场趋势与发展

  • 近期发展
  • 併购

第 14 章：全球偏头痛治疗市场：SWOT 分析

第 15 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代治疗类型的威胁

第 16 章：竞争格局

  • Amgen Inc.
  • Teva Pharmaceutical Industries Limited
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Bausch Health Companies Inc.
  • Novartis AG
  • AbbVie Inc.
  • Lundbeck Inc
  • Dr. Reddy's Laboratories Limited
  • Impel Pharmaceuticals Inc

第 17 章：策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 16304

The Global Migraine Therapeutics Market was valued at USD 3.89 Billion in 2024 and is projected to reach USD 5.01 Billion by 2030, growing at a CAGR of 4.31% during the forecast period. This market is expanding steadily due to the rising incidence of migraine, growing patient awareness, and rapid advancements in drug development. Migraine, a chronic neurological condition, affects a significant global population, leading to strong demand for effective treatment options. A notable shift is occurring toward more targeted and individualized therapies, supported by ongoing innovations such as calcitonin gene-related peptide (CGRP) inhibitors and gepants, which are demonstrating promising clinical outcomes. Increased recognition of migraine's public health and economic impacts has also driven investment in R&D by both public and private sectors. With pharmaceutical companies focusing on introducing next-generation drugs and biologics, the market continues to evolve toward more effective and personalized treatment strategies. These innovations, along with greater awareness and improved access to healthcare, are expected to support sustained market growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.89 Billion
Market Size 2030USD 5.01 Billion
CAGR 2025-20304.31%
Fastest Growing SegmentPain-Relieving Medications
Largest MarketNorth America

Key Market Drivers

High Prevalence of Migraine

The widespread occurrence of migraine is a key driver fueling the growth of the Migraine Therapeutics Market. Migraine affects individuals of all ages, genders, and demographics, making it a pervasive public health issue. The condition is a leading cause of disability and contributes to significant losses in productivity, impacting both individuals and economies. As per a March 2024 WHO report, around 40% of the global population-approximately 3.1 billion people-suffered from migraines and other headache disorders as of 2021. The condition shows a higher prevalence among women, likely due to hormonal factors. Migraine ranks among the top three neurological disorders from childhood through late adulthood. This widespread burden has led to increased attention from healthcare stakeholders, driving awareness, diagnosis, and treatment. The rising recognition of migraine's impact on quality of life has also encouraged the development and uptake of more effective therapies, including CGRP inhibitors and gepants, further expanding the market.

Key Market Challenges

Drug Development Complexity

Developing effective migraine therapeutics presents significant challenges due to the complex nature of the condition. Migraine manifests with diverse symptoms and triggers, requiring a deep understanding of its neurological basis for effective drug design. Identifying precise molecular targets is difficult, as the underlying mechanisms of migraine are still not fully understood. The clinical trial process for migraine treatments can be lengthy and costly, involving large patient populations and extended follow-up periods. Subjective symptom reporting and placebo responses add further complexity. Regulatory agencies such as the FDA require comprehensive evidence of safety and efficacy, necessitating rigorous testing and data collection. In addition, evolving clinical trial endpoints demand constant adaptation from researchers and sponsors. These challenges, combined with high development costs, can delay innovation and restrict market entry, particularly for smaller firms.

Key Market Trends

Precision Medicine

Precision medicine is emerging as a transformative trend in the Migraine Therapeutics Market, offering more effective and individualized treatment strategies. By utilizing genetic, molecular, and clinical data, precision medicine allows for the customization of therapies based on a patient's unique migraine profile. Advances in genetic testing and biomarker analysis enable pharmaceutical developers and healthcare providers to better identify subgroups of patients who are most likely to benefit from specific treatments. This targeted approach improves treatment outcomes, reduces side effects, and enhances patient satisfaction. For pharmaceutical companies, precision medicine increases the efficiency of drug development and can lead to faster regulatory approvals. It also offers the potential for higher market differentiation and pricing power. As demand grows for more personalized healthcare solutions, the integration of precision medicine into migraine treatment protocols is expected to expand significantly, reshaping the market landscape and improving therapeutic success rates.

Key Market Players

  • Amgen Inc.
  • Teva Pharmaceutical Industries Limited
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Bausch Health Companies Inc.
  • Novartis AG
  • AbbVie Inc.
  • Lundbeck Inc
  • Dr. Reddy's Laboratories Limited
  • Impel Pharmaceuticals Inc

Report Scope:

In this report, the Migraine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Migraine Therapeutics Market, Therapeutics:

  • Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others)
  • Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)

Migraine Therapeutics Market, Route of Administration:

  • Oral & Nasal
  • Injectables

Migraine Therapeutics Market, Distribution Channel:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Others

Migraine Therapeutics Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Migraine Therapeutics Market.

Available Customizations:

Migraine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

  • 4.1. Ongoing Clinical Trials
  • 4.2. Completed Clinical Trials
  • 4.3. Terminated Clinical Trials
  • 4.4. Breakdown of Pipeline, By Development Phase
  • 4.5. Breakdown of Pipeline, By Status
  • 4.6. Breakdown of Pipeline, By Therapeutic Area
  • 4.7. Breakdown of Pipeline. By Region
  • 4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global Migraine Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutics {Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)}
    • 6.2.2. By Route of Administration (Oral & Nasal, Injectables)
    • 6.2.3. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2024)
  • 6.3. Market Map

7. North America Migraine Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutics
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Migraine Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutics
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Migraine Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutics
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Migraine Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutics
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel

8. Europe Migraine Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutics
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Migraine Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutics
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. United Kingdom Migraine Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutics
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Italy Migraine Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutics
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. France Migraine Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutics
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Migraine Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutics
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Migraine Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutics
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Migraine Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutics
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. India Migraine Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutics
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Japan Migraine Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutics
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. South Korea Migraine Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapeutics
        • 9.3.4.2.2. By Route of Administration
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Australia Migraine Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapeutics
        • 9.3.5.2.2. By Route of Administration
        • 9.3.5.2.3. By Distribution Channel

10. South America Migraine Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutics
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Migraine Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutics
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Argentina Migraine Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutics
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Colombia Migraine Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutics
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Migraine Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapeutics
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Migraine Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapeutics
        • 11.3.1.2.2. By Route of Administration
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Migraine Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapeutics
        • 11.3.2.2.2. By Route of Administration
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Migraine Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapeutics
        • 11.3.3.2.2. By Route of Administration
        • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions

14. Global Migraine Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Treatment Types

16. Competitive Landscape

  • 16.1. Amgen Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Teva Pharmaceutical Industries Limited
  • 16.3. GlaxoSmithKline plc
  • 16.4. Eli Lilly and Company
  • 16.5. Bausch Health Companies Inc.
  • 16.6. Novartis AG
  • 16.7. AbbVie Inc.
  • 16.8. Lundbeck Inc
  • 16.9. Dr. Reddy's Laboratories Limited
  • 16.10. Impel Pharmaceuticals Inc

17. Strategic Recommendations

18. About Us & Disclaimer